ABOUT THE EXPERT
Joel M. Gelfand,
Professor of Dermatology and Epidemiology
Perelman School of Medicine
University of Pennsylvania
Joel M. Gelfand, MD, MSCE, is professor of dermatology and epidemiology (with tenure) at the University of Pennsylvania’s Perelman School of Medicine. He is also vice-chair of clinical research and medical director of the Dermatology Clinical Studies Unit, and director of the Psoriasis and Phototherapy Treatment Center.
He is a nationally and internationally recognized expert in psoriasis, clinical epidemiology, drug safety, and clinical trials. Dr Gelfand is the author of more than 260 scientific publications, editorials, reviews, and text book chapters (cited more than18,000 times, H index 60) that appear in journals such as The Journal of the American Medical Association , The BMJ , the European Heart Journal , the Annals of Rheumatic Disease , JAMA Dermatology , the Journal of the American Academy of Dermatology , and the Journal of Investigative Dermatology . He is the recipient of numerous awards, including the American Skin Association’s Psoriasis Achievement Award, Penn Medicine’s Marjorie A. Bowman New Investigator Research Award and the Lady Barbara Colyton Prize for Autoimmune Research, Penn Medicine Department of Biostatistics and Epidemiology’s Epidemiology Teaching Award, and the National Psoriasis Foundation’s inaugural Outstanding Scientific Achievement Award.
Dr Gelfand is an elected member of the American Society for Clinical Investigation. He cochairs the National Psoriasis Foundation’s COVID-19 Task Force and is a member of the International Psoriasis Council Board of Directors. He has given more than 10 named lectureships and keynote addresses, including the Society for Investigative Dermatology’s Eugene M. Farber Lecture and the American Academy of Dermatology’s Marion B. Sulzberger, MD, Memorial Award and Lectureship. He has received grant support from the National Institutes of Health,, the US Food and Drug administration, the Patient-Centered Outcomes Research Institute, the Dermatology Foundation, the American Skin Association, the National Psoriasis Foundation, and numerous pharmaceutical companies to support his independent research program. The overarching goal of his research and clinical practice is to improve psoriasis patient outcomes in the skin and joints, while lowering the risk of diabetes, cardiovascular disease, and mortality.